140 related articles for article (PubMed ID: 22264223)
1. Emerging role of cetuximab in the treatment of colorectal cancer.
Papa A; Rossi L; Lo Russo G; Giordani E; Spinelli GP; Zullo A; Petrozza V; Tomao S
Recent Pat Anticancer Drug Discov; 2012 May; 7(2):233-47. PubMed ID: 22264223
[TBL] [Abstract][Full Text] [Related]
2. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.
Larsen FO; Pfeiffer P; Nielsen D; Skougaard K; Qvortrup C; Vistisen K; Fromm AL; Jørgensen TL; Bjerregaard JK; Hoegdall E; Jensen BV
Acta Oncol; 2011 May; 50(4):574-7. PubMed ID: 21529301
[TBL] [Abstract][Full Text] [Related]
5. Panitumumab after progression on cetuximab in KRAS wild-type metastatic colorectal cancer patients: a single institution experience.
Marino A; Caliolo C; Sponziello F; Nacci A; Quaranta A; Mazzoni E; Lutrino SE; Rizzo P; Calvani N; Orlando L; Schiavone P; Fedele P; D'Amico M; Chetrì MC; Cinefra M; Ferrara P; Cinieri S
Tumori; 2015; 101(5):524-8. PubMed ID: 26045117
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
8. Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis.
Petrelli F; Barni S;
Int J Colorectal Dis; 2012 Aug; 27(8):997-1004. PubMed ID: 22358385
[TBL] [Abstract][Full Text] [Related]
9. Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients.
Maréchal R; De Schutter J; Nagy N; Demetter P; Lemmers A; Devière J; Salmon I; Tejpar S; Van Laethem JL
BMC Cancer; 2010 Jun; 10():340. PubMed ID: 20591136
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
[TBL] [Abstract][Full Text] [Related]
11. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
12. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab in the treatment of patients with colorectal cancer.
Garrett CR; Eng C
Expert Opin Biol Ther; 2011 Jul; 11(7):937-49. PubMed ID: 21557708
[TBL] [Abstract][Full Text] [Related]
14. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
[TBL] [Abstract][Full Text] [Related]
15. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
Lièvre A; Bachet JB; Boige V; Cayre A; Le Corre D; Buc E; Ychou M; Bouché O; Landi B; Louvet C; André T; Bibeau F; Diebold MD; Rougier P; Ducreux M; Tomasic G; Emile JF; Penault-Llorca F; Laurent-Puig P
J Clin Oncol; 2008 Jan; 26(3):374-9. PubMed ID: 18202412
[TBL] [Abstract][Full Text] [Related]
16. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.
Sohn BS; Kim TW; Lee JL; Ryu MH; Chang HM; Kang YK; Park HS; Na YS; Jang SJ; Kim JC; Lee JS
Oncology; 2009; 77(3-4):224-30. PubMed ID: 19738388
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.
Saltz L; Badarinath S; Dakhil S; Bienvenu B; Harker WG; Birchfield G; Tokaz LK; Barrera D; Conkling PR; O'Rourke MA; Richards DA; Reidy D; Solit D; Vakiani E; Capanu M; Scales A; Zhan F; Boehm KA; Asmar L; Cohn A
Clin Colorectal Cancer; 2012 Jun; 11(2):101-11. PubMed ID: 22055112
[TBL] [Abstract][Full Text] [Related]
18. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Ruzzo A; Graziano F; Canestrari E; Magnani M
Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
[TBL] [Abstract][Full Text] [Related]
19. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
Huang MY; Chen MJ; Tsai HL; Kuo CH; Ma CJ; Hou MF; Chuang SC; Lin SR; Wang JY
Genet Mol Res; 2011 Oct; 10(4):3002-12. PubMed ID: 21968808
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab in metastatic colorectal cancer.
Broadbridge VT; Karapetis CS; Price TJ
Expert Rev Anticancer Ther; 2012 May; 12(5):555-65. PubMed ID: 22594891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]